Member Contact: Tracy Weimar
Position: VP, Operations & Finance and Company Secretary
Industry: Biotech & Pharmaceuticals
ImmuPharma plc (LSE: IMM) is a drug discovery and development company headquartered in London with development operations in France. ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. ImmuPharma is currently developing drug candidates across three main programs: lupus (Phase III), cancer (Phase I) and diabetes (pre-clinical). LupuzorTM, a potential treatment for the autoimmune chronic inflammatory disease lupus, is ImmuPharma’s most advanced drug candidate having commenced its pivotal Phase III trial in December 2015. LupuzorTM was successfully licensed to US specialty pharmaceutical company, Cephalon, in 2009 in a $500 million licensing deal. In late 2011, following the acquisition of Cephalon by Teva Pharmaceuticals, ImmuPharma regained all rights to LupuzorTM.
ImmuPharma has significant collaboration arrangements with the Centre National de la Recherche Scientifique (CNRS), the largest basic research organisation in Europe. ImmuPharma also has links with the Institut National de la Sante et de la Recherche Medicale (INSERM), France’s national institute for health and medical research. ImmuPharma is led by a commercially focused Board and management team with extensive industry experience.